Abstract
Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Molecularly Targeted Therapy in Breast Cancer: The New Generation
Volume: 3 Issue: 2
Author(s): Zeina A. Nahleh
Affiliation:
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Abstract: Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Export Options
About this article
Cite this article as:
Nahleh A. Zeina, Molecularly Targeted Therapy in Breast Cancer: The New Generation, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638794
DOI https://dx.doi.org/10.2174/157489208784638794 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Assays for Identification of Hsp90 Inhibitors and Biochemical Methods for Discriminating their Mechanism of Action
Current Topics in Medicinal Chemistry Breast Cancer in the Personal Genomics Era
Current Genomics HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Current Medicinal Chemistry Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets <i>In Vivo</i> Anti-Tumor Effects of Flavokawain A in 4T1 Breast Cancer Cell-Challenged Mice
Anti-Cancer Agents in Medicinal Chemistry Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Opinion Paper: Promise and Pragmatism in Clinical Microbiome Research
Mini-Reviews in Medicinal Chemistry Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) Cratylia mollis Lectin: A Versatile Tool for Biomedical Studies
Current Bioactive Compounds Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?
Current Molecular Pharmacology Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Genetic Polymorphisms of Human Sulfate Transporters
Current Pharmacogenomics